The relationship between clinical stage, risk factors, and outcome for patients with limited disease.
| Clinical Stage . | Stage-Modified IPI Risk Factors* . | Treatment . | 5-Year Median Survival . | Limited Stage . | Proposed Description . |
|---|---|---|---|---|---|
| * For stage-modified IPI risk factors see Table 2. | |||||
| Abbreviations: IPI, International Prognosis Index; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone | |||||
| I, IE | 0 | CHOP(3) + RT | > 90% | Yes | Very limited |
| I, IE, II, IIE (no bulky II) | ≥ 1 | CHOP(3) + RT | 70% | Yes | Limited |
| Bulky II, Bulky IIE | ≥ 1 | CHOP(8) | 50% | No | Advanced |
| Clinical Stage . | Stage-Modified IPI Risk Factors* . | Treatment . | 5-Year Median Survival . | Limited Stage . | Proposed Description . |
|---|---|---|---|---|---|
| * For stage-modified IPI risk factors see Table 2. | |||||
| Abbreviations: IPI, International Prognosis Index; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone | |||||
| I, IE | 0 | CHOP(3) + RT | > 90% | Yes | Very limited |
| I, IE, II, IIE (no bulky II) | ≥ 1 | CHOP(3) + RT | 70% | Yes | Limited |
| Bulky II, Bulky IIE | ≥ 1 | CHOP(8) | 50% | No | Advanced |